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to DTCA. RESULTS: After watching the TV advertisement of
Lipitor®, 89.3% of study participants agreed that they would
talk to their physicians about their cholesterol, 88.7% agreed
that they would ask their physicians to test their cholesterol
levels, and 47.3% agreed that they would ask their doctors to
write them a prescription for Lipitor®. The study also found that
26.0% of study participants had inadequate functional health lit-
eracy, 17.3% had marginal functional health literacy, and 56.7%
had adequate health literacy. Participants who rated the adver-
tisement as helpful responded more favorably to it. Older
patients were more likely to agree to talk to doctors about cho-
lesterol. Those who had a history of high cholesterol were more
likely to agree to ask doctors to test their cholesterol levels.
CONCLUSIONS: African American patients in this study
responded more favorably to DTCA. DTCA may be an effective
marketing tool for pharmaceutical companies. However, the net
public health and economic effects of DTCA remain to be 
determined.
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OBJECTIVE: Surveys have indicated that use of alternative
treatments is increasing in the United States. One survey in found
that 33.8% of Americans were using some form of alternative
medicine and a later survey found that use had increased to
42.1% in 1997. The objective is to provide an estimate of the
prevalence of Complementary and Alternate Medicine (CAM)
use by hypertensive patients in the United States. METHODS:
Cross-sectional analysis of the 2001–2003 Medical Expenditure
Panel Survey, a nationally representative sample of the U.S. non-
institutionalized civilian population. Patients with hypertension
were identiﬁed by ICD-9-CM code of 401. Use and costs of
CAM in patients with hypertension were compared with those
in non-hypertensive individuals. Student’s t test statistics was
used to compare the costs associated with CAM use between the
two groups. Multiple logistic regression was used to determine
independent predictors of CAM use in individuals with hyper-
tension, controlling for age, sex, race/ethnicity, household
income, educational level, and co-morbidity. RESULTS: Individ-
uals with hypertension were 1.3 times more likely to use CAM
than individuals without hypertension (8 vs. 5%, P < 0.0001).
The data showed that the prevalence of CAM use among hyper-
tensives not living in metropolitan statistical areas was twice that
of living in metropolitan statistical areas (2.9% vs 1.5%; P =
0.02). Among individuals with hypertension, older age (65 years)
and higher educational attainment were independently associ-
ated with CAM use. The mean amount in dollars spent per
person for CAM was not different in both groups ($414 ± 269
vs. $236 ± 26, P = 0.5106). CONCLUSIONS: These ﬁndings
have many implications for the way we understand CAM use
among hypertensives, both for clinical applications and future
research. The data provide a baseline estimate of CAM use
among hypertensives in the United States.
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OBJECTIVES: The ALLHAT ﬁndings (December 2002) recom-
mended thiazide-type diuretics for ﬁrst-step therapy in uncom-
plicated hypertensive patients, rather than either calcium channel
blockers (CCBs) or angiotensin-converting enzyme (ACE)
inhibitors. The objective of this study was to examine prescrib-
ing patterns for antihypertensive agents in Region Emilia
Romagna (RER), Italy, following the ALLHAT publication.
METHODS: We studied automated pharmacy claims of approx-
imately 4 million RER residents between January 1, 2000 and
December 31, 2003. We computed the monthly relative per-
centage of ﬁlled prescriptions for six antihypertensive classes: thi-
azide-type diuretics, ACE inhibitors or angiotensin receptor
blockers (ARBs), CCBs, beta-blockers, alpha-blockers, and
other-type antihypertensive diuretics. A stepwise auto-regressive
forecasting model was used for time series analysis. To assess the
impact of the ALLHAT guidelines on use of each antihyperten-
sive class, predicted relative percentages and 95% conﬁdence
intervals were calculated for the 12 months of 2003. RESULTS:
During the study period, ACE inhibitors/ARBs and CCBs had
the largest relative percentages (approximately 40% and 30%,
respectively), while the relative percentages for beta-blockers and
thiazide-type diuretics were roughly 10% and 1%, respectively.
Use of thiazide-type diuretics and ACE inhibitors/ARBs showed
an overall upward trend, which was not statistically associated
with the ALLHAT publication. The relative percentage of CCBs
diminished over time and was statistically signiﬁcant compared
with that predicted by the time-series model in the last four
months of 2003 (p < 0.05). The percentage of beta-blockers was
stable during the study period, although statistically signiﬁcantly
higher in the last 7 months of 2003 compared with the predicted
values (p < 0.05). Use of alpha-blockers and other-type antihy-
pertensive diuretics was steady over time. CONCLUSIONS: The
well-publicized ALLHAT ﬁndings had a limited impact on the
prescribing patters of antihypertensive drugs in Italy. Further
research should investigate why physicians appeared to be unre-
sponsive to the new clinical evidence.
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OBJECTIVES: Statins reduce morbidity and mortality in the
prevention of cardiovascular disease (CVD). Clinical trials have
shown that the lower the cholesterol level obtained, the lower
the risk of (CVD). Therefore, the use of high doses of statins is
often encouraged. Rosuvastatin is the most potent statin but cho-
lesterol changes obtained with the lower doses can also be
reached by increasing the dose of atorvastatin or simvastatin.
The aim of this study is to assess the impact of dose increases on
the cost-effectiveness of statins in Belgium. METHODS: A state-
transition model with a 20-year time horizon using 6-month
cycles was developed in MSExcel. Individuals enter the model
CVD free. Depending on age, smoking status, systolic blood
pressure, total cholesterol (TC) and HDL-cholesterol, CVD risk
(cardiac death, non-fatal MI, angina, fatal and non-fatal stroke)
was calculated using the SCORE equation. The STELLAR-study,
which compared the efﬁcacy of rosuvastatin, atorvastatin, and
simvastatin across doses, served as data source (reduction in TC
with 10mg rosuvastatin, 20mg atorvastatin and 80mg simvas-
tatin approximately equal). Ofﬁcial sources for cost of events
and costs of the different statins were used (Belgian payers per-
spective). 3% discounting was applied on costs and effects.
